Literature DB >> 12882506

Clinical result of prolonged primary chemotherapy in retinoblastoma patients.

Jeong Hun Kim1, Young Suk Yu, Sang In Khwarg, Hyoung Soo Choi, Hee Young Shin, Hyo Seop Ahn.   

Abstract

This study evaluated the effects of prolonged primary chemotherapy in retinoblastoma. The data for 27 eyes in 22 children who were treated for retinoblastoma with up to 13 cycles of primary chemotherapy was reviewed. The chemotherapy consisted of etoposide, vincristine, and either carboplatin or ifosfamide. In bilateral retinoblastoma, 1 eye was in each Ia, Ib, and Va, according to the Reese-Ellsworth classification, 2 in each IIa, IIIa, and IIIb, 4 in IIb, and 5 in IVa. Enucleation was performed in I in IIa and 1 in Va. In unilateral, 1 was in each IIa, IIIa, IVa, IVb, and Vb, and 4 in Va. Enucleation was performed in 8 with the exception of 1 in IIa. Complete regression was observed in 17 eyes (12 patients). There was no toxicity severe enough to delay treatment. Prolonged primary chemotherapy can be considered as an alternative treatment for retinoblastoma in III or less.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12882506     DOI: 10.3341/kjo.2003.17.1.35

Source DB:  PubMed          Journal:  Korean J Ophthalmol        ISSN: 1011-8942


  9 in total

1.  Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds.

Authors:  David H Abramson; Xunda Ji; Jasmine H Francis; Federica Catalanotti; Scott E Brodie; Larissa Habib
Journal:  Br J Ophthalmol       Date:  2018-06-06       Impact factor: 4.638

2.  Eye-preserving therapy in retinoblastoma: prolonged primary chemotherapy alone or combined with local therapy.

Authors:  Joo Young Shin; Jeong Hun Kim; Young Suk Yu; Sang In Khwarg; Ho Kyung Choung; Hee Young Shin; Hyo Seop Ahn
Journal:  Korean J Ophthalmol       Date:  2010-08-03

3.  Tumor Environment of Retinoblastoma, Intraocular Cancer.

Authors:  Dong Hyun Jo; Jin Hyoung Kim; Jeong Hun Kim
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  Clinical results of chemotherapy based treatment in retinoblastoma patients: a single center experience.

Authors:  Hyery Kim; Ji Won Lee; Hyoung Jin Kang; Hyeon Jin Park; Yoon Yi Kim; Hee Young Shin; Young Suk Yu; Il Han Kim; Hyo Seop Ahn
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

Review 5.  Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class-A Meta-Analysis.

Authors:  Anthony B Daniels; Shriji N Patel; Ronald W Milam; Sahar Kohanim; Debra L Friedman; Tatsuki Koyama
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

6.  Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review.

Authors:  David H Abramson; Brian P Marr; Scott E Brodie; Ira Dunkel; Sotiria Palioura; Y Pierre Gobin
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

7.  Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma.

Authors:  Jasmine H Francis; Y Pierre Gobin; Ira J Dunkel; Brian P Marr; Scott E Brodie; Gowtham Jonna; David H Abramson
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

8.  Establishment of the relationship between tumor size and range of histological involvement to evaluate the rationality of current retinoblastoma management.

Authors:  Jianhua Yan; Hao Zhang; Yongping Li
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

9.  Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis.

Authors:  Qiuying Chen; Bin Zhang; Yuhao Dong; Xiaokai Mo; Lu Zhang; Wenhui Huang; Hua Jiang; Jiejun Xia; Shuixing Zhang
Journal:  BMC Cancer       Date:  2018-04-27       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.